Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | S100A4 | P26447 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31219515 | 0.85 | ALDH1A1 (0.64) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| SCHEMBL1181388 | 0.85 | ALDH1A1 (0.64) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| SCHEMBL29353815 | 0.82 | CYP3A4 (0.69) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| SCHEMBL78293 | 0.82 | CYP3A4 (0.69) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| Nitrogen SCHEMBL28796008 | 0.82 | ALDH1A1 (0.60) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| SCHEMBL4970698 | 0.81 | SMN1; SMN2 (0.50) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| SCHEMBL3277269 | 0.80 | PTPRC (0.54) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| SCHEMBL30317899 | 0.80 | PTPRC (0.54) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| SCHEMBL31435677 | 0.80 | CYP3A4 (0.67) | TDP1ALDH1A1CYP3A4TSHRGAA | |
| Hydrochloric Acid SCHEMBL970605 | 0.80 | CYP3A4 (0.67) | TDP1ALDH1A1CYP3A4TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 767 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| CN-105646234-A | 2-bromo-5-nitrophenylamine and preparation method thereof | 叶芳 | 2016-06-08 | — | — | CN | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015328-A1 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2026-01-15 | — | — | US | disclosed |
| EP-4663628-A1 | NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Samjin Pharmaceutical Co., Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-4652154-A1 | NOVEL ALPK1 INHIBITORS | Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-0533267-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0533266-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0280156-B1 | PROCESS FOR THE PREPARATION OF ACETOACETYLARYLAMIDES-HETEROARYLAMIDES RESPECTIVELY OF DEACTIVED AROMATIC COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0280156-A2 | Process for the preparation of acetoacetylarylamides-heteroarylamides respectively of deactived aromatic compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-31 | — | — | EP | disclosed |
| EP-0065811-B1 | DISPERSE AZOPYRIMIDINE DYESTUFFS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-02 | — | — | EP | disclosed |
| EP-0081157-B1 | PROCESS FOR THE PREPARATION OF N-NITROARYL-NITROARYL CARBOXAMIDES | BAYER AG (DE) | 1985-01-02 | — | — | EP | disclosed |
| EP-0081157-A1 | Process for the preparation of N-nitroaryl-nitroaryl carboxamides | BAYER AG (DE) | 1983-06-15 | — | — | EP | disclosed |
| EP-0065811-A1 | Disperse azopyrimidine dyestuffs | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015328-A1 | ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | TDP1 265/4885ALDH1A1 4484/4885CYP3A4 4323/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | TDP1 303/4885ALDH1A1 3106/4885CYP3A4 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.